Skip to main
LQDA
LQDA logo

LQDA Stock Forecast & Price Target

LQDA Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 58%
Buy 25%
Hold 0%
Sell 17%
Strong Sell 0%

Bulls say

Liquidia Corp is a biopharmaceutical company poised for growth in the pulmonary hypertension market, particularly through its innovative product YUTREPIA, which is anticipated to capture a share of an expanding market valued at $3B-$4B. The company’s commitment to developing its sustained-release liposomal treprostinil formulation, L606, is expected to differentiate it from existing options by enhancing drug exposure and tolerability for both PAH and PH-ILD patients. With approximately $204 million in cash as of September 30, 2024, Liquidia is well-positioned to support the upcoming launch of YUTREPIA, bolstering its financial outlook and strategic initiatives.

Bears say

Liquidia Corp's recent financial performance has shown significant challenges, highlighted by a net loss of $23.2 million, or $0.30 per share for the third quarter of 2024. The company's stock performance was negatively impacted by a delay in FDA approval for its product, YUTREPIA, which faced heightened competition from established players, such as United Therapeutics and Actelion, further complicating commercialization efforts. Additionally, key risks remain, including the possibility of failing to secure capital for future operations and not achieving revenue projections due to market constraints and competitive pressures.

LQDA has been analyzed by 12 analysts, with a consensus rating of Buy. 58% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Liquidia Technologies Inc (LQDA) Forecast

Analysts have given LQDA a Buy based on their latest research and market trends.

According to 12 analysts, LQDA has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Liquidia Technologies Inc (LQDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.